Ready to redefine wellness and experience the IV Essence difference
Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F
Unlike traditional GLP-1 peptides, Retatrutide targets three metabolic receptor pathways: GLP-1 (Glucagon-Like Peptide-1) GIP (Glucose-Dependent Insulinotropic Polypeptide) Glucagon receptors Its triple-agonist activity is being researched for its potential role in: Appetite regulation and satiety Reduced food cravings and food noise Metabolic efficiency Energy expenditure and fat metabolism Insulin sensitivity and glucose regulation Long-term body weight management support Many individuals researching Retatrutide report: Strong appetite suppression Reduced snacking tendencies Increased feelings of fullness Consistent metabolic support Significant body composition changes over time Because Retatrutide also activates glucagon receptors, ongoing research is exploring its potential role in increasing metabolic activity and energy expenditure beyond traditional GLP-1 pathways
In a phase III randomized controlled trial, 966 patients with mild-to-moderate MASH (stage F1b, F2 or F3) were randomly assigned to once-daily oral treatment with 80 mg or 100 mg resmetirom or placebo for 52 weeks 4
[54:32] A Oh, my God
Co-Enzyme Q10 supports energy production at cellular level
